# FDA Approves Sandoz Generic Drug Application Sandoz received FDA approval for an abbreviated new drug application (ANDA216068) on April 20, 2026, potentially expanding the company's generic portfolio and enabling it to compete in an additional therapeutic market segment. The approval could strengthen Sandoz's position in the competitive generic pharmaceutical space while providing cost-effective treatment options to patients and healthcare systems.